https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.full.pdfwatch?v=5d0CBZs4RJY&feature=youtu.be

Hi everybody. Around 10 days ago, I participated in an online conference about aging, organized by HEALES and ILA, and Harold Katcher was one of the speakers. As each speaker had only 15 minutes for their presentation (and Harold spoke only for 10 minutes because he had some technical issues with Zoom), I thought that it would be a good idea to make an interview with him so that he has more time to speak about his rejuvenation therapy with E-5, the test with dogs, the timeframe for the arrival of the therapy for humans, and, above all else, his theory of aging. So, it’s a more informal conversation, but I think it helps everybody to know more about Harold Katcher, maybe one of the most (if not the most) influent people in human history.

Harold Katcher, one of the discoverers of the human breast cancer gene and possibly the discoverer of the greatest rejuvenation therapy to date, talks to Nicolas Chernavsky about his rejuvenation therapy with E-5, his carreer and his theory of aging. 2020 paper on experiments with E-5: https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.full.pdfredirect?event=video_description&redir_token=QUFFLUhqbUtrUEZnT0RvbTIwR1VKMGNXVEVlZ09fdWJhUXxBQ3Jtc0trRlVvS1pnWWVlQ09yUHd1R2dCbE1wczJjT2dmbVJCczdJZUtEN18zOGhDR1Z6Q1VabWRBZHIzeEpyY1c0TTJuQXgzUXBmUmFNa24xY0F0Q3VZbjRkeTJ5dFhwM1pKcWZ0WFdmQTJwazkxRTZfbGlGaw&q=https%3A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.1101%2F2020.05.07.082917v1.full.pdf Harold’s 2013 paper on aging: https://link.springer.com/article/10.1134/S0006297913090137 Conboy’s 2005 paper on parabiosis: https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.full.pdfredirect?event=video_description&redir_token=QUFFLUhqbUlCb3pmRDlHekJVUjdBOGEtN2NwODNUa3pvQXxBQ3Jtc0traVZ3YlhPUFBRWHBLQ2l4OGMxa2hyMl9FQmNGeDI0TDA1ejdycnR1NEx3dk13b2U3UVRfRU9qWDFmUDhxWXNOT0tJZkttdkl2UUpEdktVQWFVZXFDMFZLdTcxcFlaalQza291RWtGa0pVUFltVW1ENA&q=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature03260 1994 paper on human breast cancer gene: https://courses.washington.edu/gs466/readings/miki.pdf Find out more about Nicolas Chernavsky and NTZ on www.ntzplural.com #rejuvenation #aging #biotechnology #health #science.

Like.

Companies that are creating rejuvenation biotechnology interventions must develop their products to target individual diseases in order to be approved by the FDA. While that is still the case, this particular FOA is intended to promote broader research that does not necessarily target individual diseases as endpoints.

The National Institutes of Aging in the United States, a component of the National Institutes of Health, is funding clinical trials for interventions that directly affect the root causes of age-related diseases.

Direct funding for trials against aging

Probably the most important and interesting part of this Funding Opportunity Announcement (FOA) is that the NIA specifically mentions “multiple chronic conditions” caused by the processes of aging along with more conventional trials that are targeted directly at specific downstream effects of aging.

The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals. The work is set to be published in the journal Nature Metabolism.

Investments into the longevity sector is stepping up, bolstered by the pandemic.